For children with unexplained fevers, painful mouth sores, and gut inflammation that resemble Behçet's disease (BD) but don't meet diagnostic criteria, a new genetic framework may provide answers. Published in the World Journal of Pediatrics on June 23, 2026, a systematic review by researchers at Peking Union Medical College Hospital in Beijing formalizes the concept of Behçet's spectrum disorders (BSD), first introduced in 2020. The BSD framework groups a diverse set of inflammatory conditions—from rare monogenic diseases to common recurrent canker sores—based on shared immune pathways, offering clinicians a roadmap for earlier recognition and genetic testing in children with atypical symptoms.
Behçet's disease is a systemic vasculitis characterized by recurrent oral and genital ulcers, but pediatric presentations are often partial or atypical, complicating diagnosis. Moreover, a growing number of monogenic autoinflammatory disorders produce nearly identical mucocutaneous and gastrointestinal symptoms yet require different treatments. This diagnostic overlap frequently leads to misdiagnosis, inappropriate therapy, and prolonged suffering. The BSD framework aims to address this by providing a mechanism-oriented lens for early recognition and genetic prioritization.
The researchers propose a tiered classification: "core Behçet's spectrum disorders" for monogenic diseases that directly converge on BD-defining inflammatory pathways, such as HA20 (caused by TNFAIP3 mutations), RELA haploinsufficiency, NFKB1 haploinsufficiency, and ELF4 deficiency. These conditions consistently feature recurrent mucocutaneous ulceration and disrupt NF-κB or JAK-STAT signaling. "Peripheral BSD" includes polygenic or multifactorial entities like recurrent aphthous stomatitis (RAS), PFAPA syndrome, DADA2, and trisomy 8-associated disease, which exhibit partial clinical overlap but lack a defining monogenic driver.
A major highlight is the identification of NF-κB and JAK-STAT as two central inflammatory hubs serving as common denominators across the spectrum, providing a rational basis for grouping these disorders. The authors also delineate exclusion criteria to distinguish true spectrum members from mimics like LIG4 deficiency and IKBKG (NEMO) mutations, sharpening diagnostic boundaries. The framework does not replace existing BD criteria but offers a mechanism-oriented approach to prioritize genetic testing in early-onset or atypical pediatric cases, significantly reducing diagnostic odysseys.
Clinically, the BSD framework enables earlier recognition of Behçet-like phenotypes and guides rational genetic testing, allowing targeted therapies such as IL-1, TNF, or JAK inhibitors for specific subsets. It also helps exclude non-spectrum mimics, avoiding unnecessary investigations and expediting effective care. Scientifically, it unifies disparate inflammatory disorders under shared pathogenic axes, fostering collaborative research and paving the way for biomarker discovery and mechanism-based trials.
"We're not saying these are all the same disease—they're not," the authors said. "But they converge on the same inflammatory circuits. If a child shows up with recurrent mouth ulcers, fever, and gut inflammation that doesn't quite fit Behçet's criteria, the BSD framework gives us a roadmap for what to test for and why." They emphasized that the framework is especially valuable in early-onset or atypical cases, where genetic testing can distinguish between conditions that look alike but respond to very different treatments.
Ultimately, this framework empowers pediatricians to move beyond trial-and-error management towards precision medicine, offering tangible hope for children with complex, refractory inflammatory conditions that have long defied conventional diagnosis and treatment. The full review is available at https://doi.org/10.1007/s12519-026-01035-4.
